MedTrace Logo

Evaluation of Erythroferrone as a New Biomarker of Erythropoesis Stimulating Agents

NCT03276910 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-09-08

No results posted yet for this study

Summary

The main objective of this research is to demonstrate the possible use of erythroferrone (ERFE) as a potential marker of recombinant human erythropoietin (rHuEpo) use to be included in the Athlete Biological Passport (PBA) developed by the World Anti-Doping Agency (WADA).

Conditions

  • Sports Drug Abuse

Interventions

DRUG

EPREX

6 doses at 50 IU/kg or 20 IU/kg in subcutaneous use

DRUG

sodium chloride AGUETTANT 0.9%

6 injections at 1ml in subcutaneous use

Sponsors & Collaborators

  • University of Milan School of Medicine

    collaborator UNKNOWN

  • Centre d'Investigation Clinique Lyon (CIC)

    collaborator UNKNOWN

  • Ecole Nationale de Ski et d'Alpinisme (ENSA)

    collaborator UNKNOWN

  • Partnership for Clean Competition

    collaborator OTHER

  • Association Athletes For Transparency

    lead OTHER

Principal Investigators

  • Catherine MD CORNU, phD · Centre d'Investigation Clinique (CIC)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-08
Primary Completion
2017-12-22
Completion
2018-06-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03276910 on ClinicalTrials.gov